Needham Maintains Buy on Heron Therapeutics, Lowers Price Target to $5
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Serge Belanger has maintained a 'Buy' rating on Heron Therapeutics (NASDAQ:HRTX), but lowered the price target from $6 to $5.
July 25, 2023 | 8:13 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Needham analyst has maintained a 'Buy' rating on Heron Therapeutics but lowered the price target from $6 to $5.
The news is directly related to Heron Therapeutics. While the 'Buy' rating is maintained, the lowering of the price target might create some uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100